Cardiol Therapeutics

BRIEF

published on 08/12/2025 at 13:36, 11 months 9 days ago

Cardiol Therapeutics: Phase II Trial Results and Positive Stock Outlook

BUY Rating Cardiol Therapeutics CardiolRx Phase II ARCHER Trial Acute Myocarditis
PRESS RELEASE

published on 08/12/2025 at 13:31, 11 months 9 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc after positive phase II trial results for CardiolRx in acute myocarditis

Cardiol Therapeutics Inc First Berlin Equity Research Phase II Trial CardiolRx Acute Myocarditis
BRIEF

published on 04/23/2025 at 15:29, 1 year 2 months ago

Cardiol Therapeutics Advances in Pivotal Phase III Study

FDA Approval Cardiol Therapeutics Phase III Study Recurrent Pericarditis CardiolRxT
PRESS RELEASE

published on 04/23/2025 at 15:24, 1 year 2 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation for Cardiol Therapeutics Inc, maintaining Buy rating and USD 8.50 target price. CardiolRxT phase III study enrollment for recurrent pericarditis (RP) shows promise for FDA approval

FDA Approval Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating CardiolRxT
BRIEF

published on 11/22/2024 at 11:11, 1 year 7 months ago

Cardiol Therapeutics Secures Buy Rating Amid Promising Trial Results

Clinical Trials BUY Rating Cardiol Therapeutics CardiolRx Drug Efficacy
PRESS RELEASE

published on 11/22/2024 at 11:06, 1 year 7 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research reaffirms BUY rating for Cardiol Therapeutics Inc. with USD8.50 price target based on positive final data for CardiolRx in treating recurrent pericarditis

Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating Reaffirmed CardiolRx
BRIEF

published on 10/28/2024 at 15:51, 1 year 8 months ago

Cardiol Therapeutics Initiates Phase II/III Clinical Trial for Recurrent Pericarditis

Clinical Trial Cardiol Therapeutics CardiolRx Recurrent Pericarditis MAVERIC-2 Trial
PRESS RELEASE

published on 10/28/2024 at 15:46, 1 year 8 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., initiating phase II/III clinical trial for recurrent pericarditis treatment with CardiolRx

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Clinical Trial Pericarditis Treatment
BRIEF

published on 06/14/2024 at 14:57, 2 years 1 month ago

Cardiol Therapeutics Inc Receives Updated 'Buy' Rating from First Berlin Equity Research

BUY Rating Cardiol Therapeutics CardiolRx Recurrent Pericarditis Phase II Study
PRESS RELEASE

published on 06/14/2024 at 14:52, 2 years 1 month ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Phase II Trial CardiolRx

Published on 07/21/2026 at 17:05, 4 hours 54 minutes ago

Caldwell Appoints Steven Price Co-Leader of Life Sciences & Healthcare Practice
Published on 07/21/2026 at 15:00, 6 hours 59 minutes ago

Four Nines Gold Begins Maiden Drill Program at Hayden Hill
Published on 07/21/2026 at 15:00, 6 hours 59 minutes ago

BlackBerry SecuSUITE Secures Renewed NIAP Common Criteria Certification, Reinforcing Leadership in Sovereign Government-Grade Secure Communications
Published on 07/21/2026 at 14:55, 7 hours 4 minutes ago

Vulcan Minerals Inc. - Drilling Completed at Carbonear Zinc-Lead SEDEX Project in Newfoundland
Published on 07/21/2026 at 14:30, 7 hours 29 minutes ago

Sarama Completes Sale of its West Australian Gold Assets

View all ACCESSWIRE

Published on 07/21/2026 at 18:50, 3 hours 9 minutes ago

Soapeya, a DN Group AG Portfolio Company, Earns Top "Excellent" Rating from Dermatest and Proves Successful in Field Use in Ghana
Published on 07/21/2026 at 18:15, 3 hours 43 minutes ago

EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/21/2026 at 17:50, 4 hours 9 minutes ago

The New Measure of an EV Isn't Range, It's Peace of Mind
Published on 07/21/2026 at 17:40, 4 hours 19 minutes ago

EQS-Adhoc: Airbus to present new mid-term outlook, strengthen commitment to profitable growth and shareholder returns during investor update
Published on 07/21/2026 at 17:37, 4 hours 21 minutes ago

EQS-Adhoc: Branicks Group AG updates the timetable for the publication of its 2025 annual and consolidated financial statements in light of ongoing restructuring negotiations

View all EQS

Published on 07/21/2026 at 18:41, 3 hours 18 minutes ago

ICADE - 2026 HY Financial Report
Published on 07/21/2026 at 18:13, 3 hours 46 minutes ago

ICADE – PR – 2026 HALF YEAR RESULTS
Published on 07/20/2026 at 18:20, 1 day 3 hours ago

Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 1 day 3 hours ago

Reporting on share buyback transactions carried out between July 8 and July 9, 2026
Published on 07/20/2026 at 17:45, 1 day 4 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News